Rapid Identification of UCA1 As a Very Sensitive and Specific Unique Marker for Human Bladder Carcinoma
Overview
Authors
Affiliations
Purpose: The most common genitourinary malignancy in China is bladder transitional cell carcinoma (TCC). Early diagnosis of new and recurrent bladder cancers, followed by timely treatment, will help decrease mortality. There are currently no satisfactory markers for bladder cancer available in clinics. Better diagnostic methods are highly demanded.
Experimental Design: In this research, we have used comprehensive expressed sequence tag analysis, serial analysis of gene expression, and microarray analysis and quickly discovered a candidate marker, urothelial carcinoma associated 1 (UCA1). The UCA1 gene was characterized and its performance as a urine marker was analyzed by reverse transcription-PCR with urine sediments. A total of 212 individuals were included in this study, 94 having bladder cancers, 33 ureter/pelvic cancers, and 85 normal and other urinary tract disease controls.
Results: UCA1 was identified as a novel noncoding RNA gene dramatically up-regulated in TCC and it is the most TCC-specific gene yet identified. The full-length cDNA was 1,439 bp, and sequence analysis showed that it belonged to the human endogenous retrovirus H family. Clinical tests showed that UCA1 assay was highly specific (91.8%, 78 of 85) and very sensitive (80.9%, 76 of 94) in the diagnosis of bladder cancer and was especially valuable for superficial G2-G3 patients (sensitivity 91.1%, 41 of 45). It showed excellent differential diagnostic performance in various urinary tract diseases without TCC.
Conclusions: UCA1 is a very sensitive and specific unique marker for bladder cancer. It could have important implications in postoperative noninvasive follow-up. This research also highlights a shortcut to new cancer diagnostic assays through integration of in silico isolation methods with translational clinical tests based on RNA detection protocols.
Pulmonary Hypertension: Molecular Mechanisms and Clinical Studies.
Adu-Amankwaah J, You Q, Liu X, Jiang J, Yang D, Liu K MedComm (2020). 2025; 6(3):e70134.
PMID: 40066229 PMC: 11892029. DOI: 10.1002/mco2.70134.
LncRNA UCA1 regulates immune micro-environment in cisplatin-induced AKI by miRNA-4498/AKT3 pathway.
Hongjun P, Mukanhaire L, Zhen L, Ting W, Hongye L, Xiaotian Z PLoS One. 2025; 20(2):e0314654.
PMID: 39937792 PMC: 11819503. DOI: 10.1371/journal.pone.0314654.
Extracellular vesicles-a new player in the development of urinary bladder cancer.
Kasinski D, Szeliski K, Drewa T, Pokrywczynska M Ther Adv Med Oncol. 2025; 17():17588359241297529.
PMID: 39850919 PMC: 11755519. DOI: 10.1177/17588359241297529.
Godiyal Y, Maheshwari D, Taniguchi H, Zinzuwadia S, Morera-Diaz Y, Tewari D Mil Med Res. 2024; 11(1):82.
PMID: 39690423 PMC: 11654217. DOI: 10.1186/s40779-024-00586-9.
Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancer.
Ge X, Shen Z, Yin Y Cancer Cell Int. 2024; 24(1):369.
PMID: 39522033 PMC: 11549762. DOI: 10.1186/s12935-024-03549-1.